What does UNIDOSE PHARMA do?

UNIDOSE PHARMA is a pharmacy in Izegem. Private Limited, started on 15 November 1999, 2 establishments.

What is the address of UNIDOSE PHARMA?

The registered office of UNIDOSE PHARMA is located at Kachtemsplein 10, 8870 Izegem.

Is UNIDOSE PHARMA still active?

Yes. According to the CBE (30 October 2026) UNIDOSE PHARMA is active, legal situation “Normale toestand”, started on 15 November 1999.

Is UNIDOSE PHARMA registered on Peppol?

Yes, UNIDOSE PHARMA is registered on the Peppol network with ID 0208:0467278989.

What is the enterprise number of UNIDOSE PHARMA?

The enterprise number of UNIDOSE PHARMA is BE0467278989.

When was UNIDOSE PHARMA founded?

UNIDOSE PHARMA was founded on 15 November 1999.

Who are the directors of UNIDOSE PHARMA?

According to the 2025 annual accounts, the directors of UNIDOSE PHARMA are: STOFIMMO BV, OLLINVEST BV, DELBEKE-AERTS BV, VIDELSA BV.

Is UNIDOSE PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 November 1999; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account; 2 establishments in the CBE.

How much profit did UNIDOSE PHARMA make in 2025?

UNIDOSE PHARMA posted a profit after taxes of € 223,596 in financial year 2025.

What is the revenue of UNIDOSE PHARMA?

As a small company, UNIDOSE PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 1,659,622.

How much does an employee at UNIDOSE PHARMA earn?

The average wage cost per full-time employee at UNIDOSE PHARMA was € 57,100 in 2025: staff costs of € 1.1 million for 19.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does UNIDOSE PHARMA have?

According to the 2025 annual accounts, UNIDOSE PHARMA has 19.2 full-time equivalents (FTE).

Does UNIDOSE PHARMA have a website?

Yes, UNIDOSE PHARMA has a website at apotheekkachtem.be.

UNIDOSE PHARMA (Private Limited) - Izegem - BE0467278989

Dossier UNIDOSE PHARMA, printed on 30 October 2026 from databakkes.be/en/0467278989/unidose-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

UNIDOSE PHARMA from Izegem, company number BE0467278989, closed financial year 2025 with a result of € 223,596 after tax. For that financial year UNIDOSE PHARMA recorded a gross margin of € 1.7 million and equity of € 889,111. Compared with financial year 2024, the result moved from € 463,287 to € 223,596. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 889,111

▲ 34% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 223,596

▼ 52% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 110,911

▼ 55% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 519,519.

People and assets in 2025

Full-time equivalents

19.2

▲ 1.8 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 1.1 million

▲ 10% vs 2024

€ 57,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 16,045

▼ 33% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 12 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1.5 million

▼ 15% vs 2024

€ 125,696 is repaid this year. At this pace the long-term loan is gone in ≈ 12 years.

Owed to suppliers

€ 750,725

▲ 112% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 217,186

▲ 70% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 955,195 Gross margin 2022: € 955,195 First fiscal year in the series	€ 1,241,968 Gross margin 2023: € 1,241,968 ▲ 30% vs 2022 (€ 955,195) Favourable step	€ 1,801,869 Gross margin 2024: € 1,801,869 ▲ 45% vs 2023 (€ 1,241,968) Favourable step	€ 1,659,622 Gross margin 2025: € 1,659,622 ▼ 8% vs 2024 (€ 1,801,869) Unfavourable step	▼ 8%
Profit after taxes	€ -199,804 Profit after taxes 2022: € -199,804 First fiscal year in the series	€ -30,343 Profit after taxes 2023: € -30,343 ▲ € 169,461 vs 2022 (€ -199,804) Favourable step	€ 463,287 Profit after taxes 2024: € 463,287 ▲ € 493,630 vs 2023 (€ -30,343) Favourable step	€ 223,596 Profit after taxes 2025: € 223,596 ▼ 52% vs 2024 (€ 463,287) Unfavourable step	▼ 52%
Equity	€ 232,571 Equity 2022: € 232,571 First fiscal year in the series	€ 202,228 Equity 2023: € 202,228 ▼ 13% vs 2022 (€ 232,571) Unfavourable step	€ 665,515 Equity 2024: € 665,515 ▲ 229% vs 2023 (€ 202,228) Favourable step	€ 889,111 Equity 2025: € 889,111 ▲ 34% vs 2024 (€ 665,515) Favourable step	▲ 34%
Total debts	€ 3,242,797 Total debts 2022: € 3,242,797 First fiscal year in the series	€ 3,482,354 Total debts 2023: € 3,482,354 ▲ 7% vs 2022 (€ 3,242,797) Unfavourable step	€ 2,895,446 Total debts 2024: € 2,895,446 ▼ 17% vs 2023 (€ 3,482,354) Favourable step	€ 2,959,400 Total debts 2025: € 2,959,400 ▲ 2% vs 2024 (€ 2,895,446) Unfavourable step	▲ 2%
Cash	€ 248,213 Cash 2022: € 248,213 First fiscal year in the series	€ 174,433 Cash 2023: € 174,433 ▼ 30% vs 2022 (€ 248,213) Unfavourable step	€ 245,375 Cash 2024: € 245,375 ▲ 41% vs 2023 (€ 174,433) Favourable step	€ 110,911 Cash 2025: € 110,911 ▼ 55% vs 2024 (€ 245,375) Unfavourable step	▼ 55%
Land & buildings	€ 1,655,902 Land & buildings 2022: € 1,655,902 First fiscal year in the series	€ 1,631,793 Land & buildings 2023: € 1,631,793 ▼ 1% vs 2022 (€ 1,655,902) Unchanged	€ 1,470,023 Land & buildings 2024: € 1,470,023 ▼ 10% vs 2023 (€ 1,631,793) Unchanged	€ 1,473,472 Land & buildings 2025: € 1,473,472 Unchanged (€ 1,470,023) Unchanged
Retained profit	€ -137,021 Retained profit 2022: € -137,021 First fiscal year in the series	€ -167,364 Retained profit 2023: € -167,364 ▼ € 30,343 vs 2022 (€ -137,021) Unfavourable step	€ 295,923 Retained profit 2024: € 295,923 ▲ € 463,287 vs 2023 (€ -167,364) Favourable step	€ 519,519 Retained profit 2025: € 519,519 ▲ 76% vs 2024 (€ 295,923) Favourable step	▲ 76%
Bank debt	€ 1,702,559 Bank debt 2022: € 1,702,559 First fiscal year in the series	€ 2,147,332 Bank debt 2023: € 2,147,332 ▲ 26% vs 2022 (€ 1,702,559) Unfavourable step	€ 1,737,496 Bank debt 2024: € 1,737,496 ▼ 19% vs 2023 (€ 2,147,332) Favourable step	€ 1,469,829 Bank debt 2025: € 1,469,829 ▼ 15% vs 2024 (€ 1,737,496) Favourable step	▼ 15%
Balance sheet total	€ 3,475,368 Balance sheet total 2022: € 3,475,368 First fiscal year in the series	€ 3,684,582 Balance sheet total 2023: € 3,684,582 ▲ 6% vs 2022 (€ 3,475,368) Unchanged	€ 3,620,289 Balance sheet total 2024: € 3,620,289 ▼ 2% vs 2023 (€ 3,684,582) Unchanged	€ 3,904,527 Balance sheet total 2025: € 3,904,527 ▲ 8% vs 2024 (€ 3,620,289) Unchanged	▲ 8%
Employees (FTE)	18 Employees (FTE) 2022: 18 First fiscal year in the series	17.1 Employees (FTE) 2023: 17.1 ▼ 0.9 vs 2022 (18) Unchanged	17.4 Employees (FTE) 2024: 17.4 ▲ 0.3 vs 2023 (17.1) Unchanged	19.2 Employees (FTE) 2025: 19.2 ▲ 1.8 vs 2024 (17.4) Unchanged	▲ 1.8

Key figures of UNIDOSE PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to UNIDOSE PHARMA?

What happened at UNIDOSE PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 223,596 (▼ 52% vs 2024). filed late Source: NBB ↗
Dec 1, 2022 New establishment in Gent. KBO
2022 STOFIMMO BV became a director. NBB
2022 OLLINVEST BV became a director. NBB
2022 DELBEKE-AERTS BV became a director. NBB
2022 VIDELSA BV became a director. NBB
Dec 22, 1999 New establishment in Izegem. KBO
Nov 15, 1999 Start of the company according to the CBE. KBO

In short

From € 199,804 loss in 2022 to € 223,596 profit in 2025.

Paid € 79,632 in corporate taxes since 2022.

Best year ever: 2024, with € 463,287 profit.

On average € 86,400 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

Videlsa 16%

The stake of Videlsa comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

UNIDOSE PHARMA

Behind UNIDOSE PHARMA are STOFIMMO BV, OLLINVEST BV, DELBEKE-AERTS BV and VIDELSA BV. The shares are held by Videlsa (16%).

Directors

According to the 2025 annual accounts

STOFIMMO BV

Director · represented by Beheyt Kristof

Also active at: Lupumed, KRISTOF BEHEYT, Zorgapotheek Maldegem

since 2022

OLLINVEST BV

Director · represented by Lien Dierickx

Also active at: Apotheek Varendries, Lupumed

since 2022

DELBEKE-AERTS BV

Director · represented by Delbeke Matthias

Also active at: APOTHEEK DELBEKE - AERTS, APOTHEEK KACHTEM, IMDELAER

since 2022

VIDELSA BV

Director · represented by Heyns Eline

since 2022

Shareholders

Videlsa

16%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Kachtemsplein 10

8870 Izegem

2.339.357.215

Raapstraat 27

9031 Gent

Active since 1 December 2022

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Website

HTTPS apotheekkachtem.be

Technologies

BootstrapChart.jsCloudflare CDNDiviElementorFacebook PixelFont AwesomeGoogle FontsOwl CarouselPHPSwiperWP RocketWPMLWooCommerceWordPressYoast SEOjQueryjQuery UIlazysizesreCAPTCHA

Hosting & Email

Email provider

Microsoft 365

Hosting

CLOUDFLARENET - Cloudflare, Inc., US

DNS

Cloudflare DNS

Website info

HTTPS Ja

Languages NL

Features

Webshop Blog Ads Contact page

Security

✓ HTTPS

✓ SPF

✗ DMARC

Network

✓ IPv6

✓ Load balancing

Details

Company number

0467.278.989

VAT number

BE 0467.278.989

Registered office

Kachtemsplein 10, 8870 Izegem

Names & denominations

UNIDOSE PHARMA

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

15 November 1999

Peppol

Active · Active since 15 May 2025

Contact

apotheekkachtem.be [email protected] 051301704

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

Verhuur en exploitatie van eigen of geleased residentieel onroerend goed, exclusief sociale woningen

View on CBE Public ↗ Annual accounts (NBB) ↗

UNIDOSE PHARMA

Financials

What happened to UNIDOSE PHARMA?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Website

Technologies

Hosting & Email

Website info

Features

Security

Network

Details

Frequently asked questions